Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Follow-Up Questions
Who is the CEO of Jupiter Neurosciences Inc?
Mr. Christer Rosen is the Chairman of the Board of Jupiter Neurosciences Inc, joining the firm since 2016.
What is the price performance of JUNS stock?
The current price of JUNS is $1.46, it has increased 2.09% in the last trading day.
What are the primary business themes or industries for Jupiter Neurosciences Inc?
Jupiter Neurosciences Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Jupiter Neurosciences Inc market cap?
Jupiter Neurosciences Inc's current market cap is $50.8M
Is Jupiter Neurosciences Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Jupiter Neurosciences Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
